• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Matters of the heart: a newly discovered type of inflammatory muscle disease with heart involvement

Matters of the heart: a newly discovered type of inflammatory muscle disease with heart involvement

October 20, 2017 By Erika Darrah

Summary

Patients with autoimmune myositis experience an attack of the muscle by the immune system, leading to muscle inflammation and weakness. There are several types of myositis, each marked by a specific antibody biomarker that may help give rheumatologists clues about potential future symptoms, effective treatments, and long-term disease prognosis. A team of researcher from the Johns Hopkins Division of Rheumatology, led by Jemima Albayda, MD and Lisa Christopher-Stine, MD, MPH, has verified that an antibody biomarker in a group of patients with myositis is associated with cardiac involvement. This confirms a previous report from 2012 noting similar findings which were unknown to the Hopkins research team at the time of their discovery (Maeda MH, et al. Inflammatory myopathy associated with antimitochondrial antibodies. Brain 2012;135:1767-1777).  These antibodies bind to a protein in the mitochondria, the energy producing factory of the cell. Usually, these antibodies are found in people with primary biliary cirrhosis, a disease where the immune system causes damage to the liver. These antibodies were also found by Dr. Christopher-Stine’s team, to be present in the blood of people with myositis who have chronic inflammation of the skeletal muscle, as well as cardiac involvement which is presumed to be inflammatory in nature.

Why was this study done?

Dr. Christopher-Stine and her team treat patients with many different forms of myositis, in the Johns Hopkins Myositis Center. Over time, they began to notice that some of their myositis patients had severe heart disease, but none of the known antibody biomarkers. They went on to find that many of these patients were positive for antimitochondrial antibodies or AMA. Based on this initial finding, the team sought to review all cases in which myositis patients had AMA and describe the clinical features of this disease subset.

How was this study done?

The research team identified patients seen at the Myositis Center who were positive for AMA and had inflammatory muscle disease. They reviewed the patients’ records to collect information on their clinical symptoms, laboratory tests, MRI images, electrophysiologic tests, and muscle biopsy results.

What were the major findings?

The researchers found that patients with AMA associated myositis often experienced a chronic disease course, with years of worsening muscle weakness prior to their diagnosis. This often led to a difficulty in doctors arriving at the correct diagnosis of myositis, and patients had severe muscle atrophy (wasting away due to underuse) by the time they were diagnosed by a rheumatologist. Heart disease was seen in 71% of these patients and took the form of myocarditis (inflammation of the heart), severe arrhythmias, or cardiomyopathy (enlargement of the heart). Although the heart disease was often not recognized to be related to the myositis, treatments that suppressed the immune system led to improvements in these symptoms.

What is the impact of this work?

This study describes a clear association of AMA with a chronic autoimmune myositis in which patients experience prominent and severe heart disease. Given the increasing evidence for such a distinct clinical entity, the authors propose that AMA should be added to the growing list of myositis-associated antibodies. They should be searched for in myositis patients with a history of severe arrhythmias, cardiomyopathy, or myocarditis. Conversely, if AMAs are noted in myositis patients, a thorough cardiac evaluation should be undertaken including EKG and echocardiography at the minimum. Early recognition of this rare form of myositis is important since prompt treatment with medications that suppress the immune system may dramatically improve disease prognosis in these patients.

This research was supported by:

The Johns Hopkins Rheumatic Disease Research Core Center (P30-AR053503) from the US National Institutes of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health; Stabler Foundation; and Huayi and Siuling Zhang Discovery Fund

Link to original research article:

Inflammatory myopathy associated with antimitochondrial antibodies: A distinct phenotype with cardiac involvement. Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L. Semin Arthritis Rheum. 2017 Jun 13. pii: S0049-0172(17)30239-1. doi: 10.1016/j.semarthrit.2017.06.004. [Epub ahead of print]

EDIT 10/24/2017 :  This article was updated to clarify that this clincial entity was previously described by Maeda, MH,  et al in the 2012 issue of Brain. As such, all claims regarding the novelty of this finding in the JHU cohort have been removed from this article.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research

Erika Darrah

Erika Darrah, Ph.D. is an Assistant Professor of Medicine in the Johns Hopkins University Division of Rheumatology with an interest understanding the mechanisms that drive the development of rheumatic diseases.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2023

LEAP Rounds – Holiday 2022

November 9, 2022

Dr. Rachel Wallwork named ACR Distinguished Fellow

October 19, 2022

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy